ClinicalTrials.Veeva
Menu

Find clinical trials for Heart Disease in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Coronary Artery Disease
Cardiovascular Diseases
Heart Failure
Myocardial Ischemia
Coronary Disease
Kidney Diseases

Heart Disease trials near Paris, Île-de-France, FRA:

Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. (AMYLOCARTESIAN)

Background: The prevalence of both senile cardiac amyloidosis (CA) and aortic stenosis (AS) markedly increases with age. Aortic stenosis inc...

Active, not recruiting
Heart Disease
Aging
Other: a basal LV septum biopsy
French Cardiology Society

Saint-Denis, France and 4 other locations

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study ...

Active, not recruiting
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: NNC6019-0001
Drug: Placebo (NNC6019-0001)

Phase 2

Novo Nordisk
Novo Nordisk

Créteil, France and 32 other locations

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe ...

Enrolling
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: NNC6019-0001

Phase 2

Novo Nordisk
Novo Nordisk

Créteil, France and 30 other locations

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic h...

Active, not recruiting
Heart Transplantation
Device: XVIVO heart preservation devices
Device: Standard ICSS
XVIVO
XVIVO

Paris, Paris Cedex, France and 14 other locations

Effectiveness of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, t...

Enrolling
Heart Defects, Congenital
Heart Diseases
Drug: Placebo
Drug: CRD-4730

Phase 2

Cardurion Pharmaceuticals

Paris, France and 10 other locations

Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD (ASCENT ASD)

Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect

Enrolling
Heart Defects, Congenital
Cardiovascular Diseases
Device: reSept ASD Occluder
atHeart Medical

Paris, France and 27 other locations

RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)

Purpose of this prospective, randomized, controlled, multi-center study is to evaluate the safety and efficacy of Transcatheter Aortic Valve Implanta...

Active, not recruiting
Heart Valve Diseases
Aortic Valve Stenosis
Procedure: Transcatheter aortic valve replacement
Optimapharm

Paris, France and 47 other locations

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 in...

Enrolling
Pulmonary Arterial Hypertension
Drug: Generic treprostinil sodium + Standard of Care (Double Oral)
Drug: Standard of Care - Double Oral

Phase 4

AOP Orphan

Paris, France and 18 other locations

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3

Amgen
Amgen

Paris, France and 851 other locations

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Phase 3

Novo Nordisk
Novo Nordisk

Paris, France and 588 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems